Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 10, 2010 - Issue 4
Submit an article Journal homepage
37
Views
2
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin

Talitha I Verhoef Utrecht University, Faculty of Science, Division of Pharmacoepidemiology and Pharmacotherapy, PO Box 80 082, 3508 TB Utrecht, The Netherlands; Utrecht University, Faculty of Science, Division of Pharmacoepidemiology and Pharmacotherapy, PO Box 80 082, 3508 TB Utrecht, The Netherlands
,
Tom Schalekamp Utrecht University, Faculty of Science, Division of Pharmacoepidemiology and Pharmacotherapy, PO Box 80 082, 3508 TB Utrecht, The Netherlands; Utrecht University, Faculty of Science, Division of Pharmacoepidemiology and Pharmacotherapy, PO Box 80 082, 3508 TB Utrecht, The Netherlands
,
William K Redekop Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands; Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands
,
Anthonius de Boer Utrecht University, Faculty of Science, Division of Pharmacoepidemiology and Pharmacotherapy, PO Box 80 082, 3508 TB Utrecht, The Netherlands; Utrecht University, Faculty of Science, Division of Pharmacoepidemiology and Pharmacotherapy, PO Box 80 082, 3508 TB Utrecht, The Netherlands
&
Anke-Hilse Maitland-van der Zee Utrecht University, Faculty of Science, Division of Pharmacoepidemiology and Pharmacotherapy, PO Box 80 082, 3508 TB Utrecht, The Netherlands;[email protected]
Pages 375-378 | Published online: 09 Jan 2014

References

  • Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics28(1), 61–74 (2010).
  • Kurnik D, Loebstein R, Halkin H, Gak E, Almog S. 10 years of oral anticoagulant pharmacogenomics. What difference will it make?. A critical appraisal. Pharmacogenomics10(12), 1955–1965 (2009).
  • Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann. Intern. Med.150(2), 73–83 (2009).
  • McWilliam A, Lutter R, Nardinelli C. Health care savings from personalizing medicine using genetic testing. the case of warfarin. AEI-Brooking Joint Center for Regulatory Studies Working Paper 06–23, (2006).
  • You JH, Tsui KK, Wong RS, Cheng G. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy. Clin. Pharmacol. Ther.86(5), 540–547 (2009).
  • Anderson JL, Horne BD, Stevens SM et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation116(22), 2563–2570 (2007).
  • Sanderson S, Emery J, Higgins J.CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients. A huge net systematic review and meta-analysis. Genet. Med.7(2), 97–104 (2005).
  • Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation. A prospective randomized controlled study. Clin. Pharmacol. Ther.83(3), 460–470 (2008).
  • Patrick AR, Avorn J, Choudhry NK. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ. Cardiovasc. Qual. Outcomes2(5), 429–436 (2009).
  • Klein TE, Altman RB, Eriksson N et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med.360(8), 753–764 (2009).
  • Van Schie RMF, Wadelius MI, Kamali F et al. Genotype-guided dosing of coumarin derivatives. The European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) trial design. Pharmacogenomics10(10), 1687–1695 (2009).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.